期刊文献+

对难治性贫血伴环状铁粒幼红细胞联合显著血小板增多的认识现状 被引量:1

原文传递
导出
摘要 1999年Gupta等[1]首次提出难治性贫血伴环状铁粒幼红细胞和血小板增多的概念,2001年第3版WHO〈造血组织和淋巴组织肿瘤分类〉提出一种暂定类型疾病"获得性铁粒幼红细胞性贫血联合血小板增多",或称"难治性贫血伴环状铁粒幼红细胞联合显著血小板增多(RARS-T)",并将其归入骨髓增生异常综合征/骨髓增殖性疾病不能分类(MDS/MPD,U).
作者 崔蕊 肖志坚
出处 《中华血液学杂志》 CAS CSCD 北大核心 2010年第12期855-857,共3页 Chinese Journal of Hematology
基金 "十一五"国家科技支撑计划(2008BAI 61B02) 国家自然科学基金(30670899) 天津市自然科学基金重点项目(08JCZJC19200)
  • 相关文献

参考文献20

  • 1Gupta R,Abdalla SH,Bain BJ.Thrombocytosis with sideroblastic erythropoiesis:a mixed myeloproliferative myelodysplastic syndrome.Leuk Lymphoma,1999,34:615-619.
  • 2Schmitt-Graeff AH,Teo SS,Olschewski M,et al.JAK2 V617F mutation status identifies subtypes of refractory anaemia with ringed sideroblasts associated with marked thrombocytosis.Haematologica,2008,93:34-40.
  • 3Wang SA,Hasserjian RP,Loew JM,et al.Refractory anaemia with ringedsideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myelo-proliferative and myelodysplastic features.Leukemia,2006,20:1641-1644.
  • 4Camaschella C.Recent advances in the understanding of inherited sideroblastic anaemia.Br J Haematol,2008,143:27-38.
  • 5Cavadini P,Biasiotto G,Poli M,et al.RNA silencing of the mitochondrial ABCB7 transporter in HeLa cells causes an iron-deficient phenotype with mitochondrial iron overload.Blood,2007,109:3552-3559.
  • 6Boultwood J,Pellagatti A,Nikpour M,et al.The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts.PLoS ONE,2008,3:e1970.
  • 7Malcovati L,Della Porta MG,Pietra D,et al.Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.Blood,2009,22,114:3538-3545.
  • 8Ceesay MM,Lea NC,Ingram W,et al.The JAK2 V61F mutation is rare in RARS but common in RARS-T.Leukemia,2006,20:2060 -2061.
  • 9Malcovati L,Cazzola M.Myelodysplastic/myeloproliferative disorders.Haematologica,2008,93:4-6.
  • 10Wardrop D,Steensma DP.Is refractory anaemia with ringsideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category? Br J Haematol,2009; 144:809-817.

同被引文献10

  • 1VARDIMAN J W, BENNETT J M, BAIN B J, et al. Myelodysplastie/myeloproliferative neoplasm, unclassifiable [M]// SWERDLOW S H,CAMPO E,HARRIS N L,et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th Ed. Lyon, France: IARC Press: 2008 : 85-86.
  • 2MALCOVATI L,DELLA PORTA M G,PIETRA D, et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis[J]. Blood, 2009,114 : 3538- 3545.
  • 3RAYA J M, ARENILLAS L, DOMINCAD A, et al. Refractory anemia with tinged sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status[J]. Int J Hematol, 2008,88 : 387 -395.
  • 4GUREVICH I, LUTHRA R, KONOPLEV S N, et al. Refractory anemia with ring sideroblasts associated with marked thrombocytosis[J]. Am J Clin Pathol, 2011,135 :398-403.
  • 5SCHMITT-GRAEFF A H, TEO S S, OLSCHEWSKI M, et al. JAK2 V617F mutation status identifies subtypes of refractory anaemia with ringed sideroblasts associated with marked thrombocytosis[J]. Haematologica, 2008, 93:34-40.
  • 6PICH A, GODIO L. Refractory anaemia with ring sideroblasts associated with marked thrombocytosis (RARS- T) and JAK2 (V617F) mutation transformed to acute myeloid leukaemia with chromosomal evolution including monosomy 7[J]. Leuk Res,2010,34:e69-e70.
  • 7SZPURKA H, JANKOWSKA A M, MAKISHIMA H, et al. Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations[J]. Leuk Res, 2010,34 : 969 -973.
  • 8CEESAY M M,LEA N C,INGRAM W,et al. The JAK2 V617F mutation is rare in RARS but common in RARS- T[J]. Leukemia, 2006,20:2060-2061.
  • 9SZPURKA H, TIU R, MURUGESAN G, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis ( RARS-T ), another myeloproliferative condition characterized by JAK2 V617F mutation [J]. Blood, 2006,108 : 2173-2181.
  • 10HULS G, MULDER A B, ROSATI S, et al. Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring siderohlasts and thrombocytosis[J]. Blood, 2010,116 : 180 - 182.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部